Misdiagnosis of olfactory neuroblastoma

ZVI R. COHEN, M.D., ERIC MARMOR, M.D., GREGORY N. FULLER, M.D., PH.D., AND FRANCO DEMONTE, M.D.

Departments of Neurosurgery and Neuropathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Object. Olfactory neuroblastoma (ON) is a rare neoplasm arising from the olfactory epithelium and found in the upper nasal cavity. The authors studied the frequency with which ON is misdiagnosed with other tumors of the paranasal sinuses such as neuroendocrine carcinoma (NEC), pituitary adenoma, melanoma, lymphoma, and sinonasal undifferentiated carcinoma (SNUC). Based on the belief that misdiagnosis commonly occurs, they emphasized the importance of establishing the correct diagnosis, because the treatment regimens and prognosis of these tumor types are often significantly different.

Methods. Twelve consecutive patients in whom ON had been diagnosed were referred to the Department of Neurosurgery at the M. D. Anderson Cancer Center between January 1998 and March 2000. Demographic data were collected, physical findings and mode of treatments were documented, and neuroimaging studies were assessed. Pathologists at the authors’ institute reviewed the histological specimens. Only in two of 12 patients was the diagnosis of ON confirmed. Lesions in 10 patients were misdiagnosed: there were two cases of melanoma, three cases of NEC, three cases of pituitary adenoma, and two cases of SNUC. Eight of 10 patients in whom lesions were misdiagnosed required significant alteration in the initially proposed treatment plan.

Conclusions. Neurosurgeons should be acutely aware of the variety of neoplasms that occur in the paranasal region. The correct diagnosis should be ensured before initiating treatment to provide the optimum therapy and spare the patients from needless and potentially toxic treatment.

Key Words • olfactory neuroblastoma • immunocytochemistry • anterior skull base • paranasal sinus tumor

Clinical Material and Methods

Twelve consecutive patients in whom ON had been diagnosed were referred to the M. D. Anderson Cancer Center over a 15-month period between January 1998 and March 2000. The hospital records were reviewed. Demographic data, presenting symptoms, physical and imaging findings, and mode of therapy (proposed or initiated) were documented. Our neuropathologist reviewed the histopathological specimens obtained in all the patients. Immunohistochemical staining of all the specimens was performed and electron microscopy was conducted in three of them to establish a definite diagnosis.

Results

In 10 patients a diagnosis of ON had been incorrectly made. Only two of the 12 lesions were ultimately confirmed to be ON. Of the 10 originally misdiagnosed neoplasms, two were confirmed to be melanoma, three to be NEC, three to be pituitary adenoma, and two to be SNUC. Of the 10 patients in whom lesions were initially misdiagnosed, seven were men and five women; their mean age at presentation was 55.9 years (range 39–79 years). Epistaxis, nasal obstruction, and headache were the most common presenting symptoms, with facial pain, decreased vision, diplopia, and proptosis occurring less frequently. As a result of misdiagnosis, eight of 10 patients required significant alteration of the treatment plan that had initially been proposed (Table 1). Two illustrative cases are described in detail, and findings in all patients are summarized in Table 1.
ILLUSTRATIVE CASES

Case 1

This 56-year-old man initially presented to an outside institution with a history of nasal obstruction. Neuroimaging studies revealed a lesion involving the sphenoid and ethmoid sinuses. There was no evidence of bone destruction, and no intracranial disease was identified. An endoscopically guided biopsy procedure was performed and a pathological diagnosis of an ON was determined. Combination radiotherapy and cisplatin chemotherapy were initiated. There was no response to this therapeutic regimen, and when the patient’s vision started to deteriorate, he underwent a second course of radio- and chemotherapy in which Adriamycin and vincristine were administered. Unfortunately, as a result of his treatment the patient became blind, and he developed panhypopituitarism as well as cardiomyopathy (Fig. 1). He was referred to our institution, and on review of his pathological and neuroimaging studies it was decided that a new biopsy of his lesion should be obtained. Results of this examination indicated that the lesion was in fact a pituitary adenoma.

Case 8

This 48-year-old man initially presented to an outside institution with a history of epistaxis. Neuroimaging studies revealed a lesion involving the nasal cavity and ethmoid sinuses. There was evidence of bone destruction but no intracranial extension of the tumor was visualized. He underwent an endoscopically guided biopsy procedure, and the neoplasm was diagnosed as ON. After surgery and postoperative radiotherapy were proposed, he presented at our institution for a second opinion. Upon review, the pathologist was not satisfied that a diagnosis of ON could be made based on the original biopsy specimen, and a second biopsy procedure was performed. Analysis of this specimen revealed an NEC. Given our success in treating these tumors without surgery,2 the patient received chemotherapy and his response was excellent. He then underwent consolidating radiotherapy and his disease remains in remission, surgical intervention having been avoided (Fig. 2).

DISCUSSION

We have presented 12 consecutive patients in whom ON was initially diagnosed who were referred to the Department of Neurosurgery at the M. D. Anderson Cancer Center between January 1998 and March 2000. After careful reexamination of their diagnostic neuroimaging and pathological studies, all but two of the original diagnoses were changed. The tumors that had been initially misdiagnosed as ONs included two melanomas, three NEC, three pituitary adenomas, and two SNUC. The change in diagnosis resulted in significantly different therapeutic interventions in eight of 10 patients, with some of the patients having suffered unnecessary morbidity.

Olfactory neuroblastomas, first described by Berger and Richard in 19243 arise from the olfactory epithelium of the nasal cavity in the region of the cribriform plate. The tumor cells are a relatively homogeneous population of small round cells set in a variable fibrillary stroma and form part of the differential diagnosis of round-cell lesions of the head and neck region.12 The presence of a fibrillary intercellular background in conjunction with the presence of Homer–Wright rosettes in an upper nasal neoplasm is considered to be diagnostic of ON.35

TABLE 1

Summary of treatment characteristics in patients in whom neoplasms were misdiagnosed as ON*

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age (yrs), Sex</th>
<th>Treatment</th>
<th>Prior</th>
<th>Recommended</th>
<th>New Diagnosis</th>
<th>Final Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>56, M</td>
<td>biopsy, XRT, chemo</td>
<td>chemo</td>
<td>chemo</td>
<td>PA</td>
<td>observation†</td>
</tr>
<tr>
<td>2</td>
<td>79, M</td>
<td>resection</td>
<td>XRT</td>
<td>XRT</td>
<td>PA</td>
<td>observation†</td>
</tr>
<tr>
<td>3</td>
<td>65, F</td>
<td>biopsy</td>
<td>XRT</td>
<td>XRT</td>
<td>PA</td>
<td>observation†</td>
</tr>
<tr>
<td>4</td>
<td>52, M</td>
<td>biopsy</td>
<td>resection, XRT</td>
<td>SNUC</td>
<td>chemo, resection, XRT</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>53, M</td>
<td>resection</td>
<td>resection, XRT</td>
<td>SNUC</td>
<td>chemo, XRT†</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>60, F</td>
<td>biopsy</td>
<td>resection, XRT</td>
<td>NEC</td>
<td>chemo, XRT†</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>39, F</td>
<td>biopsy</td>
<td>chemo, resection</td>
<td>NEC</td>
<td>chemo, XRT†</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>48, M</td>
<td>biopsy</td>
<td>resection, XRT</td>
<td>NEC</td>
<td>chemo, XRT†</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>68, M</td>
<td>biopsy</td>
<td>chemo, resection, XRT</td>
<td>melanoma</td>
<td>resection, XRT</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>39, M</td>
<td>resection, XRT</td>
<td>chemo, resection</td>
<td>melanoma</td>
<td>chemo†</td>
<td></td>
</tr>
</tbody>
</table>

*Chemo = chemotherapy; PA = pituitary adenoma; XRT = radiotherapy.
† Patients in whom a significant change in therapy was made due to reclassification of the neoplasm.
Misdiagnosis of olfactory neuroblastoma

Olfactory neuroblastoma account for between 1 to 5% of malignant nasal cavity neoplasms and occur in all age groups with bimodal peaks in the second and fifth decades. Common presenting symptoms include nasal obstruction and epistaxis; facial pain, diplopia, proptosis, and anosmia are less frequently reported. Neuroimaging studies of ONs are nonspecific. Compared with gray matter, the signal on T₁-weighted MR images is either hypo- or isointense. On T₂-weighted MR images, the signal varies from iso- to hyperintense. Contrast enhancement is intense and of variable uniformity, with some degree of gadolinium enhancement displayed in most cases. Various staging systems have been proposed to provide better treatment guidelines and predictors of prognosis. The pathological grade of the tumor was found to be the most significant prognostic factor, with an 80% 5-year survival rate and a 40% 5-year survival rate for low-grade and high-grade tumors, respectively.

Regardless of the grade, or stage—with the possible exception of distant metastasis—surgery is the recommended mainstay of therapy in patients harboring these tumors. Multidisciplinary, aggressive craniofacial resection appears to yield the best results. Surgical treatment alone is effective in cases of low-grade tumor if tumor-free margins can be obtained. The use of adjuvant radiotherapy is supported for low-grade tumors when the margins are close, for residual or recurrent disease, and for all high-grade tumors. Some authors have argued that radiation is best administered preoperatively whereas others prefer to administer it postoperatively and yet others recommend postoperative radiotherapy for Stage A tumors and preoperative radiotherapy for higher-stage lesions (Stages B and C). Given the rarity of ONs, it is unlikely that the optimum timing of adjuvant radiotherapy will ever be clearly determined. More recently, chemotherapy, combined with resection and radiotherapy, has been used to treat advanced-stage, high-grade, and recurrent ONs with durable remission periods. There are anecdotal reports of cases with unresectable lesions in which long-term survival was achieved following a combination of chemotherapy and radiotherapy. It appears that high-grade tumors show the greatest response to cisplatin-based chemotherapeutic treatment.

Neuroendocrine carcinomas of the nasal cavity and paranasal sinus are exceedingly uncommon neoplasms recognized as a separate entity from ONs by both Kameya, et al., and Silva, et al., in the early 1980s. These tumors are thought to originate from the glandular epithelium of the exocrine glands found in the normal olfactory mucosa. They occur in older patients (mean age 50 years) compared with patients with ON, and they seldom involve the cribiform plate, confirming the hypothesis that they originate lower in the nasal vault. They are composed of sheets and nests of small- to intermediate-sized cells with a high nucleo/cytoplasmatic ratio, hyperchromatic nuclei, and high mitotic rates. The most commonly reported presenting symptoms are nasal obstruction and epistaxis. Less frequent presenting symptoms include facial pain, anosmia, and exophthalmos. These neoplasms have been shown to expand into and cause destruction of the sinuses; however, no distinctive neuroimaging characteristics have been identified on computerized tomography or MR imaging. Because these lesions are rare, their optimum treatment has not yet been definitively ascertained. Some investigators have advocated the use of resection in the treatment of these tumors. Our more recent experience at the M. D. Anderson Cancer Center indicates that NEC can be effectively treated using a combined regimen of chemotherapeutic and radiotherapy without the need for resection. The successful treatment of these tumors without surgical intervention is further supported by Chaudhry and colleagues who have reported a patient in whom a paranasal sinus NEC was diagnosed, who has remained disease free for 5 years after undergoing radiotherapy alone.

Sinonasal undifferentiated carcinomas were first recognized as a distinct entity from ONs by Frierson and his colleagues in 1986. Consisting of medium-sized cells arranged in nests and sheets with wide trabeculae, these tumors often contain extensive necrosis and vascular permeation. Although few series have been reported in the literature, the epidemiology and clinical presentation for these tumors, mainly epistaxis and nasal obstruction, appear to be similar to those for ONs as well as NECs. Sinonasal undifferentiated carcinoma cannot be distinguished from other tumors of this region (with the possible exception of melanoma) based on neuroimaging features. In a recent study the authors suggested that the staging and grading systems commonly used for ON are also applicable for SNUC. The prognosis for patients with SNUC, however, is considerably less favorable than for those with ON; the overall cure rate is less than 20% and most patients die within 1.5 years of disease onset. Righi, et al., reported a mean survival of only 11.5 months following treatment. The optimum treatment for these tumors remains uncertain. Overall survival associated with SNUC is extremely poor regardless of the treatment regimens used. Initial combination chemotherapy and radiotherapy in all cases of SNUC regardless of disease extent, followed by resection if intracranial involvement or metastatic disease are absent. Righi, et al., recommended radical resection and adjuvant therapy for patients with isolated and locally advanced disease; however, palliative chemotherapy and radiotherapy without surgery are preferable in cases in which extensive intracranial involvement and distant
metastatic disease are present. In a recent paper the author recommended that resection in patients with intracranial disease should not be performed until a response to adjuvant therapy has been demonstrated.20

Lymphomas arising from the paranasal sinuses are distinctly less common in Western than in Asian populations, accounting for only 0.17% of all lymphomas in the former group and 0.44% of all extranodal malignant lymphomas.16 Although virtually every subtype of lymphoma was found to occur in the paranasal sinuses in one large study, the B-cell phenotype has a slight predominance in Western countries and the natural killer–T/NK-cell phenotype predominates in Asian and South American countries.31 Sinonasal lymphomas commonly occur in the sixth to eighth decades of life with a 2:1 male/female ratio.47 Patients with these tumors frequently present with nasal obstruction and facial swelling. Other less common symptoms include epistaxis, facial pain, diplopia and nasal discharge.9,47 In a recent review of the literature, Logsdon, et al.,31 reported a 5-year survival rate for patients with these tumors ranging from 12 to 86%. In their own large series of 70 patients, the same authors reported an overall 5-year survival rate of 52%.31 In the past these lymphomas were treated with local radiotherapy alone with good response; however, a high incidence of local and distance recurrences were reported.2 The authors of recent reports have recommended a combination of chemotherapy and local irradiation as the optimum treatment for sinonasal lymphomas.31,47 Radiotherapy alone is considered insufficient for treatment of patients with advanced disease.31 In patients who undergo chemotherapy alone there is a higher risk of local recurrence.30 As in the case of other lymphomas, definitive resection has not been advocated as appropriate therapy for sinonasal lymphomas.19

Pituitary tumors involving the paranasal sinuses most commonly arise secondarily to invasion from an intrasellar tumor or rarely as a result of an ectopic focus.32 Ectopic pituitary adenomas are speculated to develop from ectopic cell rests that have been entrapped along the pathway of the craniohypophyseal duct during embryonic development or that have aberrantly migrated.33 These tumors share the wide histological spectrum of other pituitary adenomas, ranging from lesions with neuroendocrine features to those resembling poorly differentiated carcinomas.32 The MR imaging–documented characteristics of paranasal sinus pituitary adenomas are those of a mass, isointense to gray matter on T1-weighted sequence with a heterogeneous pattern of enhancement.35 Patients harboring these tumors may present with nasal obstruction or epistaxis.32,46 Analysis of the literature suggests that sinonasal pituitary adenomas in general may be more aggressive than regular pituitary adenomas because many of the former are more frequently invasive macroadenomas.32 Regardless of their pathogenesis, these tumors should be treated as regular pituitary adenomas with initial attempts at controlling prolactinomas with bromocriptine and at attempting for complete resection for all other tumors.32

Sinonasal melanoma is an uncommon tumor constituting 4.8% of all neoplasms in this region.33 These neoplasms, which have migrated from the neuroectoderm, are the source of mucosal melanomas. They are composed of a variety of cells that may be round, oval, polygonal, epithelioid, or spindle shaped.9 They occur predominantly in patients in their fifth through eighth decade of life.17 The most common presenting symptoms are epistaxis and nasal obstruction.4,17 Sinonasal melanomas are aggressive tumors with a 5-year survival rate of 36% reported in a metaanalysis of 163 patients.7 Resection is the treatment of choice for these tumors.6,9,17 The role of adjuvant radiotherapy is more controversial and is unlikely to have more than a modest effect on survival.6,9 There is no routine role for chemotherapy in the treatment of mucosal melanoma, and this therapeutic mode should be reserved for use in randomized clinical trials.9

All of the aforementioned tumors are rarely seen, even in specialized centers. Clinical and neuroimaging features of these paranasal sinus neoplasms cannot reliably be used to establish a correct diagnosis. In fact, the clinical and neuroimaging characteristics identified in the series of misdiagnosed tumors presented in this study were all compatible with the diagnosis of ON. The prognosis and treatment paradigms, however, vary significantly for the different types of tumors that can occur in the paranasal sinus region. As a result, it is our recommendation that in all patients presenting with paranasal sinus tumor, an adequate biopsy sample be obtained and reviewed by an experienced pathologist in collaboration with the treating physician, prior to initiation of any definitive therapy.

The pathological differentiation of these tumors can be a difficult task, even for an experienced pathologist, requiring special staining procedures and occasionally electron microscopy. Pituitary adenomas are usually cytologically bland tumors in which there are regular round nuclei, a delicate chromatin pattern, and only rare mitotic figures. Homer–Wright rosettes are not invariably seen, but their presence can aid in making the diagnosis of ON. Sinonasal undifferentiated carcinoma, NEC, lymphomas, and melanomas are all generally high-grade tumors with frequent mitotic figures and pleomorphic nuclei. A battery of immunohistochemical stains is widely available and is indispensable for characterizing tumors arising from the paranasal sinus region. The staining characteristics of these tumors are summarized in Table 2. Some of the staining characteristics of ON, NEC, and SNUC are presented in Fig. 3. Of all the paranasal sinus tumors, it is most difficult to differentiate ON from NEC, and despite the usefulness of immunohistochemistry, electron microscopy may be required to distinguish these two neo-

### Table 2

**Characteristics of immunohistochemical testing of paranasal sinus tumors**

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Neuronal Markers</th>
<th>Keratin</th>
<th>Pituitary Hormones</th>
<th>S-100</th>
<th>HMB-45 (LCA)</th>
<th>CD45</th>
</tr>
</thead>
<tbody>
<tr>
<td>ON</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>SNUC</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>NEC</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>pituitary adenoma</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>melanoma</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>lymphoma</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
</tbody>
</table>

* + = frequent presence of staining; – = frequent absence of staining; +/- = staining variably present.
Ultrastructurally, ONs consist of blastic cells with neuroendocrine granules, dendritic processes, and nerve endings with synaptic structures, whereas NEC have rare neuroendocrine granules, simple cytoplasmic borders, and, most importantly, no dendritic processes. Moreover, electron microscopy is useful in the diagnostic categorization of other sinonasal tumors as well. Electron microscopy studies of SNUC show ultrastructural characteristics of closely apposed cell membranes with occasional attachment cell junctions; however, they do not have dense core granules, dendritic process, or synaptic structures. Lymphomas are characterized by the absence of cell attachment junctions, whereas melanomas have the ultrastructurally diagnostic appearance of melanin granules.

In summary we recommend the use of immunohistochemical and electron microscopy studies to differentiate between the variety of round-cell neoplasms arising in the sinonasal region to establish the accurate diagnosis, which is vital for providing the optimum treatment for patients.

CONCLUSIONS

Tumors arising from the paranasal sinus region are relatively rare. Clinicians treating patients with these tumors must be aware of the spectrum of neoplasms that occur in this region. Definitive treatment of these tumors should not be initiated until a thorough neuroimaging examination and subsequent biopsy sampling are undertaken. A spectrum of immunohistological tools is available to help distinguish the often otherwise similar pathological features that these tumors share. Furthermore, in some instances electron microscopy may be necessary to establish the diagnosis. The treatment regimens for these tumor types are often significantly different from the accepted treatment of ONs. Ensuring that a correct diagnosis is made before starting treatment will spare the patient from needless and potentially toxic therapy.

References
